INTRODUCTION

The term “eclampsia” is derived from a word meaning “like a flash of lightning.” This is the occurrences of generalized convulsions, associated with signs of pre-eclampsia during pregnancy, labor, or within 7 days of delivery and not caused by epilepsy or other convulsive disorders. Some authors considered that eclampsia can occur up to 10 days following delivery. Eclampsia remains an important cause of maternal and perinatal morbidity and mortality worldwide.1-3 It is estimated that it accounts for more than 50,000 maternal deaths globally.2 A large majority of these...
deaths occur in low-income countries where the quality of maternity care is often inadequate. Although it affects around 1–2% of the pregnant women population, it contributes approximately 10% of maternal morbidity in India and other developing countries. In Europe and other developed countries, eclampsia complicates about 1 in 2000 deliveries, while in the developing countries, estimates vary widely from 1 in 100 to 1 in 1700. The incidence of eclampsia has reduced considerably in the developing countries due to good antenatal care (ANC) and increased awareness within the population. The incidence quoted from the leading centers of India varies from 0.18% to 4.6% and approximately 75% of cases occur in primigravidae. Maternal mortality according to various Indian authors is 8–14% but a low maternal mortality was reported by Menon. In fact, worldwide maternal morbidity varies widely at different places with almost identical management indicating that there may be important differences in socioeconomic condition of a nation and the quality of obstetric care. Early assessment of severity of pre-eclampsia and eclampsia is necessary to prevent complications such as HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome and increased maternal and fetal morbidity and mortality.

Aims and objectives
Hence, the present prospective case–control study was done at our tertiary care center to assess the severity of eclampsia and coagulopathy by a method that is rapid, cheaper, and easily available and to assess the clinical evaluation and comparison of the fetomaternal outcomes in eclampsia with normal and deranged coagulation profiles.

MATERIALS AND METHODS
The present hospital-based prospective case–control study was done on 100 patients of eclampsia who were admitted in our tertiary care center to assess the severity of pre-eclampsia, eclampsia, and coagulopathy by a method that is rapid, cheap, and easily available and to assess the clinical evaluation and comparison of the fetomaternal outcomes in eclampsia with normal and deranged coagulation profiles.

Study design
This was a hospital-based prospective case–control study.

Study duration
The study duration was 1.5 years (February 2018–August 2019).

Study area
The study was done at our tertiary care institute in the Department of Obstetrics and Gynaecology, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra.

Study population
All pregnant women attending the ANC outpatient department (OPD) with new onset of grand mal seizure activity and/or unexplained coma during pregnancy or postpartum with signs or symptoms of pre-eclampsia who fulfilled the inclusion criteria.

Sample size
One hundred patients. Considering a confidence level of 95% and confidence interval of 10, the number of patients in our study to achieve statistical significance is 96. This was calculated by survey system.

Inclusion criteria
All pregnancies and gestational age >20 weeks were included in the study.

Exclusion criteria
Pregnant women with known case of bleeding disorders were excluded from the study.

The study was done in the Department of Obstetrics and Gynaecology, ANC OPD, after due permission from the Institutional Ethics Committee and Review Board and after taking written valid informed consent from the patients. After approval from the Institutional Ethics Committee, a valid informed consent was taken. Once the patients were enrolled for the study, a thorough history and physical examination was done as per pro forma. An informed consent was taken in written from patients and/or patient's attendant(s).

Complete clinical examination was done at the start of the study. The anthropometric parameters such as height and weight of subject were measured. Blood pressure (BP) was measured with patients in supine position and resting comfortably on her right hand at 30° to the horizontal with the sphygmomanometer cuff at the level of the heart. Fetal status evaluated with non-stress test and ultrasonographical evaluation if required.

Treatment included rest, control of BP (antihypertensive drugs), and Inj. MgSO as per Pritchard’s regimen, strict monitoring of input/output, deep tendon reflexes, and vital signs monitoring. Obstetric management done by termination of pregnancy and by giving steroid prophylaxis for eclampsia patients with preterm gestation.

Ethical clearance
The study was conducted after obtaining written approval from the Institutional Ethics Committee. Written informed
consent was taken from every study patient or their logical representative.

**Statistical analysis**

The data were checked and entered into Excel sheet and analyzed with Microsoft Excel and SPSS version 20. Quantitative data are presented with the help of mean and standard deviation. Comparison among the study groups is done with the help of unpaired t-test as per results of normality test. Qualitative data are presented with the help of frequency and percentage table. Association among the study groups is assessed with the help of Fisher test, Student’s ‘t’-test, and Chi-square test. “P”<0.05 is taken as statistically significant.

**RESULTS**

A hospital-based prospective case–control study was undertaken with 100 eclampsia patients admitted during the study period to study the fetomaternal outcomes in eclampsia in correlation to the coagulation profile.

A total number of deliveries during the study period from February 2018 to August 2019 were 4342. During the study period all 100 patients with eclampsia based on account of inclusion and exclusion criteria were included in the study. Overall incidence of eclampsia was found to be 2.4%.

Majority of the eclampsia patients in both normal coagulation profile group and deranged coagulation profile group were in the age group of 21–25 years (42.8% and 46.6%, respectively) followed by 21.4% of patients with normal coagulation profile in the age group of 16–20 years and 33.3% of patients with deranged coagulation profile in the age group of 16–20 years and 33.3% of patients with deranged coagulation profile. About 14.29% of the eclampsia patients with normal coagulation profile were 21–25 years old and that with deranged coagulation profile was 24.8 years old. Majority of the eclampsia patients were primigravidae, in both the groups, that is, 75.71% of the patients with normal coagulation profile and 40% of the patients with deranged coagulation profile. About 14.29% of the eclampsia patients with normal coagulation profile were 2nd gravida whereas 23.33% of the patients with deranged coagulation profile belonged to both 2nd gravida and 3rd gravida groups. Majority of the patients with normal coagulation profile, that is, 57.14% were of 34–36 weeks gestation followed by 24.29% of patients of 34–36 weeks gestational age. Among patients with deranged coagulation profile, 43.33% of them were of 36–40 weeks gestation followed by 26.67% of them belonging to 34–36 weeks gestational age (Table 1).

Out of the 100 eclampsia patients, 89% had platelet count above 1.5 lakh/cu. mm and 11% had thrombocytopenia.

Mean hemoglobin of normal coagulation profile group was 9.85 g% while that of deranged coagulation profile group was 10.66 g% and P=0.084 (not significant). Mean platelet count of normal coagulation profile group was 238,665 while that of deranged coagulation profile group was 238,665 and P=0.001 (significant). Mean serum bilirubin of normal coagulation profile group was 0.484 while that of deranged coagulation profile group was 0.484 (not significant). Mean serum glutamate oxaloacetate transaminase (SGOT) of normal coagulation profile group was 38.91 while that of deranged coagulation profile group was 56.27 and P=0.004 (not significant). Mean serum glutamate pyruvate transaminase (SGPT) of normal coagulation profile group was 165153 and P=0.142 (not significant).

The overall incidence of eclampsia was found to be 2.4%.

### Table 1: Distribution of patients according to age, parity, and gestational age

| Age            | Normal coagulation profile | Deranged coagulation profile |
|----------------|---------------------------|------------------------------|
| 16–20 years    | 15 (21.4%)                | 4 (13.3%)                    |
| 21–25 years    | 30 (42.8%)                | 14 (46.6%)                   |
| 26–30 years    | 14 (20%)                  | 10 (33.3%)                   |
| 31–35 years    | 8 (11.4%)                 | 2 (6.6%)                     |
| 36–40 years    | 3 (4.2%)                  | 2 (6.6%)                     |
| Total          | 70 (100%)                 | 30 (100%)                    |
| Mean           | 24.61 years               | 24.8 years                   |
| Parity         |                           |                              |
| Primigravida   | 53 (75.71%)               | 12 (40%)                     |
| 2nd gravida    | 10 (14.29%)               | 7 (23.33%)                   |
| 3rd gravida    | 4 (5.71%)                 | 7 (23.33%)                   |
| 4th gravida    | 2 (2.86%)                 | 3 (10%)                      |
| 5th gravida    | 1 (1.43%)                 | 1 (3.33%)                    |
| Total          | 70 (100%)                 | 30 (100%)                    |
| Gestational age|                           |                              |
| <32 weeks      | 6 (8.57%)                 | 2 (6.67%)                    |
| 32–34 weeks    | 1 (1.43%)                 | 5 (16.67%)                   |
| 34–36 weeks    | 17 (24.29%)               | 8 (26.67%)                   |
| 36–40 weeks    | 40 (57.14%)               | 13 (43.33%)                  |
| >40 weeks      | 6 (8.57%)                 | 2 (6.67%)                    |
| Total          | 70 (100%)                 | 30 (100%)                    |
of normal coagulation profile group was 0.798 while that of deranged coagulation profile group was 0.803 and P=0.899 (not significant). Mean PT of normal coagulation profile group was 13.42 s while that of deranged coagulation profile group was 18.39 and P=0.00001 (significant). Mean INR of normal coagulation profile group was 1.017 while that of deranged coagulation profile group was 1.616 and P=0.000004 (significant). Mean sodium of normal coagulation profile group was 139.56 while that of deranged coagulation profile group was 139.57 and P=0.991 (not significant). Mean serum potassium of normal coagulation profile group was 4.217 while that of deranged coagulation profile group was 3.941 and P=0.004 (significant) (Table 4).

Of the 70 patients with normal coagulation profile, 37.1% had pallor and 65.7% had pedal edema, and no patient had icterus, whereas of the 30 patients with deranged coagulation profile, 20% had pallor, 76.6% had pedal edema, and 6.6% had icterus. Majority of the eclamptic patients with normal coagulation profile (41.43%) had a hemoglobin of 7-9.9g% and deranged coagulation profile (46.67%) had a hemoglobin of ≥11 g%. Among the cohort of normal coagulation profile, three patients had deranged liver function tests (LFTs), out of which two of them had normal serum bilirubin with deranged SGOT/SGPT. Among the cohort of deranged coagulation profile, all the four patients had complete deranged LFT. Majority of the fetal Doppler studies were found to be normal with 88.57% being in eclamptic patients with normal coagulation profile and 83.33% being in those with deranged coagulation profile. About 8.57% of the patients with normal coagulation profile had fetoplacental insufficiency whereas 6.67% among those with deranged coagulation profile had uteroplacental insufficiency. Out of the remaining cases, there were two intrauterine fetal deaths (IUFDs) among patients with normal coagulation profile and three IUFDs among patients with deranged coagulation profile. Majority of the eclamptic patients in both the groups had deranged liver function tests (LFTs) among those with normal coagulation profile and 70% among those with deranged coagulation profile (Table 5).

The most common maternal outcome in the eclampsia patients with both normal (50%) and deranged (36.6%) of normal coagulation profile group was 0.798 while that of deranged coagulation profile group was 0.803 and P=0.899 (not significant). Mean PT of normal coagulation profile group was 13.42 s while that of deranged coagulation profile group was 18.39 and P=0.00001 (significant). Mean INR of normal coagulation profile group was 1.017 while that of deranged coagulation profile group was 1.616 and P=0.000004 (significant). Mean sodium of normal coagulation profile group was 139.56 while that of deranged coagulation profile group was 139.57 and P=0.991 (not significant). Mean serum potassium of normal coagulation profile group was 4.217 while that of deranged coagulation profile group was 3.941 and P=0.004 (significant) (Table 4).

Of the 70 patients with normal coagulation profile, 37.1% had pallor and 65.7% had pedal edema, and no patient had icterus, whereas of the 30 patients with deranged coagulation profile, 20% had pallor, 76.6% had pedal edema, and 6.6% had icterus. Majority of the eclamptic patients with normal coagulation profile (41.43%) had a hemoglobin of 7-9.9g% and deranged coagulation profile (46.67%) had a hemoglobin of ≥11 g%. Among the cohort of normal coagulation profile, three patients had deranged liver function tests (LFTs), out of which two of them had normal serum bilirubin with deranged SGOT/SGPT. Among the cohort of deranged coagulation profile, all the four patients had complete deranged LFT. Majority of the fetal Doppler studies were found to be normal with 88.57% being in eclamptic patients with normal coagulation profile and 83.33% being in those with deranged coagulation profile. About 8.57% of the patients with normal coagulation profile had fetoplacental insufficiency whereas 6.67% among those with deranged coagulation profile had uteroplacental insufficiency. Out of the remaining cases, there were two intrauterine fetal deaths (IUFDs) among patients with normal coagulation profile and three IUFDs among patients with deranged coagulation profile. Majority of the eclamptic patients in both the groups had deranged liver function tests (LFTs) among those with normal coagulation profile and 70% among those with deranged coagulation profile (Table 5).

The most common maternal outcome in the eclampsia patients with both normal (50%) and deranged (36.6%)

### Table 2: Distribution of patients according to platelet count, INR (normal INR=0.6–1.2), prothrombin time (normal PT=11–16), bleeding time (normal BT=3–5 min), and clotting time (normal CT=4–10 min)

| Platelet count       | Frequency | Percentage |
|----------------------|-----------|------------|
| Normal platelet count| 89        | 89%        |
| Thrombocytopenia     | 11        | 11%        |
| Total                | 100       | 100%       |
| INR                  |           |            |
| Normal               | 79        | 79%        |
| Deranged             | 21        | 21%        |
| PT                   |           |            |
| Normal               | 79        | 79%        |
| Deranged             | 21        | 21%        |
| BT                   |           |            |
| Normal               | 92        | 92%        |
| Deranged             | 8         | 8%         |
| CT                   |           |            |
| Normal               | 93        | 93%        |
| Deranged             | 7         | 7%         |

INR: International normalized ratio, PT: Prothrombin time, BT: Bleeding time, CT: Clotting time

### Table 3: Association of hemoglobin, platelets, bilirubin, SGOT, and SGPT with coagulation profiles

| Hemoglobin          | N   | Mean   | Standard deviation | Minimum | Maximum | F     | P value |
|---------------------|-----|--------|--------------------|---------|---------|-------|---------|
| Not deranged coagulation | 70  | 9.85   | 2.10               | 5.9     | 14.3    | 3.042 | 0.084   |
| Deranged coagulation  | 30  | 10.86  | 2.11               | 6       | 15.4    |       |         |
| Total               | 100 | 10.099 | 2.12               |         | 15.4    | 12.814| 0.001   |
| Platelets           |     |        |                    |         |         |       |         |
| Not deranged coagulation | 70  | 238665.7| 89353.05           | 104000  | 583000  |       |         |
| Deranged coagulation  | 30  | 165153.3| 104561.2           | 17200   | 336000  |       |         |
| Total               | 100 | 216612 | 99566.61           | 17200   | 583000  |       |         |
| Bilirubin           |     |        |                    |         |         |       |         |
| Not deranged coagulation | 70  | 0.4847 | 0.28132            | 0.2     | 2.4     | 8.47  | 0.004   |
| Deranged coagulation  | 30  | 1.17   | 1.93554            | 0.2     | 7.4     |       |         |
| Total               | 100 | 0.6903 | 1.11901            | 0.2     | 7.4     |       |         |
| SGOT                |     |        |                    |         |         |       |         |
| Not deranged coagulation | 70  | 38.91  | 38.814             | 10      | 261     | 2.188 | 0.142   |
| Deranged coagulation  | 30  | 56.27  | 78.625             | 11      | 330     |       |         |
| Total               | 100 | 44.12  | 54.081             | 10      | 330     |       |         |
| SGPT                |     |        |                    |         |         |       |         |
| Not deranged coagulation | 70  | 33.24  | 34.439             | 11      | 277     | 2.4   | 0.125   |
| Deranged coagulation  | 30  | 48.2   | 61.595             | 11      | 234     |       |         |
| Total               | 100 | 37.73  | 44.559             | 11      | 277     |       |         |

SGOT: Serum glutamate oxaloacetate transaminase, SGPT: Serum glutamate pyruvate transaminase
coagulation profile was operative intervention, that is, lower segment cesarean section (LSCS), followed by the requirement of maternal intensive care in critical care unit (CCU) or medical intensive care unit (MICU). Out of the 7 (23.33%) patients with deranged coagulation profile who required intensive care monitoring, four succumbed. No maternal mortality was encountered among the eclampsia patients with normal coagulation profile. The least common maternal outcomes among patients with normal coagulation profile were disseminated intravascular coagulation (DIC) and acute renal failure accounting for 2.86% of cases each and that among patients with deranged coagulation profile was acute renal failure accounting for 6.67% of cases. Majority of the babies is 50% among those with normal coagulation profile and 56.66% among those with deranged coagulation profile group had prematurity.

Table 4: Association of urea, creatinine, PT, INR, sodium, and serum potassium with coagulation profiles

|                  | N   | Mean | Standard deviation | Minimum | Maximum | F    | P value |
|------------------|-----|------|--------------------|---------|---------|------|---------|
| **Urea**         |     |      |                    |         |         |      |         |
| Not deranged coagulation | 70  | 23.49| 7.199              | 15      | 54      | 0.034| 0.853   |
| Deranged coagulation    | 30  | 23.77| 6.263              | 16      | 35      |      |         |
| Total               | 100 | 23.57| 6.901              | 15      | 54      |      |         |
| **Creatinine**      |     |      |                    |         |         |      |         |
| Not deranged coagulation | 70  | 0.798| 0.163              | 0.4     | 1.6     | 0.016| 0.899   |
| Deranged coagulation    | 30  | 0.803| 0.186              | 0.5     | 1.5     |      |         |
| Total               | 100 | 0.801| 0.169              | 0.4     | 1.6     |      |         |
| **PT**             |     |      |                    |         |         |      |         |
| Not deranged coagulation | 70  | 13.42| 1.6229             | 10      | 16      | 42.21| 0.0001  |
| Deranged coagulation    | 30  | 18.39| 5.9355             | 11      | 37      |      |         |
| Total               | 100 | 14.91| 4.1704             | 10      | 37      |      |         |
| **INR**            |     |      |                    |         |         |      |         |
| Not deranged coagulation | 70  | 1.017| 0.143              | 0.7     | 1.31    | 46.703| 0.0004  |
| Deranged coagulation    | 30  | 1.616| 0.704              | 0.6     | 3.5     |      |         |
| Total               | 100 | 1.197| 0.485              | 0.6     | 3.5     |      |         |
| **Sodium**         |     |      |                    |         |         |      |         |
| Not deranged coagulation | 70  | 139.56| 3.541             | 130     | 146     | 0    | 0.991   |
| Deranged coagulation    | 30  | 139.57| 4.264             | 132     | 145     |      |         |
| Total               | 100 | 139.56| 3.751             | 130     | 146     |      |         |
| **Serum potassium** |     |      |                    |         |         |      |         |
| Not deranged coagulation | 70  | 4.217| 0.460              | 3.2     | 5.4     | 8.642| 0.004   |
| Deranged coagulation    | 30  | 3.941| 0.353              | 3.2     | 4.7     |      |         |
| Total               | 100 | 4.134| 0.448              | 3.2     | 5.4     |      |         |

INR: International normalized ratio, PT: Prothrombin time

Table 5: Distribution of patients according to general examinations and tests

| General examinations and tests | Total | Normal coagulation profile | Deranged coagulation profile |
|--------------------------------|-------|-----------------------------|-----------------------------|
| Pallor                         | 32    | 26 (37.1%)                   | 6 (20%)                     |
| Icterus                        | 2     | 2 (6.6%)                     | -                           |
| Pedal edema                    | 69    | 46 (65.7%)                   | 23 (76.6%)                  |
| Hemoglobin ≥11 g%              | 22    | 14 (46.67%)                  | 8 (28.57%)                  |
| 10–10.9 g%                     | 13    | 6 (20%)                      | 7 (23.33%)                  |
| 7–9.9 g%                       | 29    | 9 (30%)                      | 20 (68.97%)                 |
| 4–6.9 g%                       | 6     | 1 (3.33%)                    | 5 (16.67%)                  |
| Total                          | 70    | 30 (100%)                    | 40 (133.33%)                |
| LFT                            |       | 26 (86.67%)                  | 3 (10.98%)                  |
| Normal LFT                     | 67    | 65 (95.71%)                  | 2 (2.87%)                   |
| Deranged LFT                   | 3     | 1 (33.33%)                   | -                           |
| Total                          | 70    | 30 (100%)                    | 40 (133.33%)                |
| Fetal Doppler                  |       | 25 (83.33%)                  | 2 (6.67%)                   |
| Normal Doppler study           | 62    | 60 (96.83%)                  | 2 (3.17%)                   |
| Feto-placental insufficiency   | 6     | 5 (83.33%)                   | 1 (16.67%)                  |
| Utero-placental insufficiency  |       | 2 (33.33%)                   | -                           |
| Total                          | 68    | 27 (40.29%)                  | 41 (59.71%)                 |
| NST                            |       | 22 (73.33%)                  | 7 (26.67%)                  |
| Reactive                       | 66    | 59 (89.39%)                  | 7 (10.61%)                  |
| Non-reactive                   | 2     | 1 (50%)                      | 1 (50%)                     |
| Total                          | 68    | 27 (40.29%)                  | 41 (59.71%)                 |

NST: Non-stress test, LFT: Liver function test
The least common fetal outcome among those with normal coagulation profile being neonatal death and still birth accounting for 2.85% of cases each whereas among those with deranged coagulation profile, the least common outcome being very low birth weight (VLBW) accounting for 3.33% of cases (Table 6).

Of the 46 eclampsia mothers who underwent operative intervention, 93.47% had normal platelet counts and 6.52% had thrombocytopenia. Of the 11 eclampsia mothers who received intensive care, 63.63% of them had normal platelet counts and 36.36% had thrombocytopenia. Of the four maternal mortalities, 25% of them had normal platelet counts and 75% had thrombocytopenia. Of the four eclampsia mothers who had acute renal failure, 50% had normal platelet counts and 50% had thrombocytopenia. Of the six eclampsia mothers who developed pulmonary edema, 100% of them had normal platelet counts. Of the 10 eclampsia mothers who had posterior reversible encephalopathy syndrome (PRES), 60% of them had normal platelet counts and 40% had thrombocytopenia. Of the four maternal mortalities, 25% of them had normal platelet counts and 75% had thrombocytopenia. Of the four eclampsia mothers who had acute renal failure, 50% had normal platelet counts and 50% had thrombocytopenia. Of the eight neonatal deaths, 50% were among those of eclampsia mothers with normal platelet count and 50% among those with thrombocytopenia. Out of 6 still births, 83.33% were among those of eclampsia mothers with normal platelet count and 16.66% were among those with thrombocytopenia. Out of six still births, 83.33% were among those of eclampsia mothers with normal platelet count and 16.66% were among those with thrombocytopenia. Out of 52 premature babies, 86.53% were among those of eclampsia mothers with normal platelet count and 13.56% were among those with thrombocytopenia. Out of 10 intrauterine growth retardation (IUGR) babies, 80% were among those of eclampsia mothers with normal platelet count and 20% were among those with thrombocytopenia (Table 7).

DISCUSSION

The present study observed a total of 4342 deliveries from February 2018 to August 2019 out of which 100 patients of eclampsia were found during the same period with the incidence of eclampsia in the present study of 2.3%, which is consistent with the reported incidence of eclampsia in India which varies from 0.179 to 3.7%.

In the present study, majority of the eclamptic patients with both normal (42.8%) and deranged (46.6%) coagulation profiles belonged to the age group of 21–25 years. About 30% of the patients had deranged coagulation profiles while 70% had normal coagulation profiles. Majority of the eclampsia patients in both normal coagulation (75.71%) and deranged coagulation (40%) profile groups were primigravidae. This is similar to the studies of Priyadarshini and Mohanty, Awolola and Enaruna and Mishra et al., Mishra et al., prospective comparative study comparing the coagulation profiles of pre-eclamptic and eclamptic women found that maximum numbers of cases were in the age group of 24–29 years. Most patients in normotensive pregnant control group and patients with pregnancy-induced hypertension (PIH) were in age group of 18–29 years.

Mishra et al., prospective comparative study comparing the coagulation profiles of pre-eclamptic and eclamptic...

| Table 6: Distribution of maternal and fetal outcome as per coagulation profile |
|-----------------------------------------------|-----------------|-----------------|-----------------|
| Maternal outcome                           | Total | Normal coagulation profile (70) | Deranged coagulation profile (30) |
| Operative intervention (LSCS)                | 46    | 35 (50%)                     | 11 (36.67%)                     |
| Intensive care                              | 11    | 4 (5.71%)                     | 7 (4 died) (23.33%)             |
| Maternal mortality                          | 4     | - (0%)                        | 4 (13.33%)                      |
| Acute renal failure                         | 4     | 2 (2.86%)                     | 2 (6.67%)                       |
| Pulmonary edema                             | 4     | 2 (5.71%)                     | 2 (6.67%)                       |
| PRES                                         | 10    | 4 (5.71%)                     | 6 (20%)                         |
| DIC                                          | 5     | 2 (2.86%)                     | 3 (10%)                         |
| Fetal outcome                               |       |                               |                               |
| Baby with mother                            | 64    | 50 (71.42%)                   | 14 (46.66%)                     |
| Neonatal death (NND)                        | 8     | 2 (2.85%)                     | 6 (20%)                         |
| Still birth                                  | 6     | 2 (2.85%)                     | 4 (13.33%)                      |
| LBW (1.5–2.5 Kg)                             | 10    | 7 (10%)                       | 3 (10%)                         |
| VLBW (1–1.5 Kg)                              | 5     | 4 (5.71%)                     | 1 (3.33%)                       |
| 5 min Apgar score <7 (RD)                   | 7     | 5 (7.14%)                     | 2 (6.67%)                       |
| Prematurity                                  | 52    | 35 (50%)                      | 17 (56.66%)                     |
| IUGR                                         | 10    | 6 (8.57%)                     | 4 (13.33%)                      |

VLBW: Very low birth weight, NND: Neonatal death, LBW: Low birth weight, LSCS: Lower segment cesarean section, DIC: Disseminated intravascular coagulation
women observed that PIH was more common in primigravida as compared to mild and severe pre-eclampsia, eclampsia was more common in primigravida.

Mishra et al., \(^\text{13}\) prospective comparative study comparing the coagulation profiles of pre-eclamptic and eclamptic women observed that maximum women were in the gestational age group of 33–40 weeks. PIH cases had significantly lesser duration of pregnancy. Gestational age at the time of admission varied from 32 weeks till term.

The parameters of the coagulation profile considered in this study are platelet count, BT, CT, PT, and INR. About 89% of the eclampsia patients had normal platelet count, while 11% had thrombocytopenia. About 92% of the eclampsia patients had normal BT, whereas 8% had deranged BT. About 93% of the eclampsia patients had normal CT, while 7% had deranged CT. About 79% of the eclampsia patients had normal INR, while 21% had deranged INR. About 79% of the eclampsia patients had normal PT, while 21% had deranged PT. This is consistent with the studies of Mishra et al., \(^\text{13}\) and Priyadarshini and Mohanty. \(^\text{11}\)

It was observed in our study that majority of the eclamptic patients with normal coagulation profile (41.43%) had a hemoglobin of 7-9.9g% and deranged coagulation profile (46.67%) had a hemoglobin of ≥11 g%. Among the eclamptic patients with normal coagulation profile, 3 (4.29%) patients had deranged LFTs, out of which two of them had normal serum bilirubin with deranged SGOT/SGPT. Among the eclamptic patients with deranged coagulation profile, all the 4 (13.33%) patients had complete deranged LFT. The correlation of deranged and normal coagulation profile with respect to Hb and platelets parameters was significant. This is in concordance to the studies of Priyadarshini and Mohanty. \(^\text{11}\)

Priyadarshini and Mohanty \(^\text{11}\) cross-sectional study observed in the study group, 13 (26%) cases had platelet count below 1 lac/mm\(^3\), out of which 2 (4%) cases had mild pre-eclampsia and 11 (22%) cases were of severe pre-eclampsia. Twenty-five (50%) cases had platelet count between 1 lac and 1.5 lacs/mm\(^3\).

In the present study, the correlation of deranged and normal coagulation profile with respect to bilirubin, SGOT, SGPT, urea, and creatinine parameters was significant. The correlation of deranged and normal coagulation profile with respect to PT, INR, serum sodium, and potassium parameters was significant. Priyadarshini and Mohanty \(^\text{11}\) and Mishra et al., \(^\text{13}\) noted similar observations in their studies.

It was observed in the present study that the most common maternal outcome in the eclampsia patients with both normal (50%) and deranged (36.6%) coagulation profile was operative intervention, that is, LSCS, followed by the requirement of maternal intensive care in CCU or MICU. Out of the 7 (23.3%) patients with deranged coagulation profile who required intensive care monitoring, four succumbed.

It was observed in our study that majority of the babies is 50% among those with normal coagulation profile and 56.66% among those with deranged coagulation profile group had prematurity. The least common fetal outcome among those with normal coagulation profile being neonatal death and still birth accounting for 2.85% of cases each whereas among those with deranged coagulation profile, the least common outcome being VLBW accounting for 3.33% of cases. Of the 46 eclampsia mothers who underwent operative intervention, 93.47% had normal platelet counts and 6.52% had thrombocytopenia. Of the 11 eclampsia mothers who received intensive care, 63.63% of them had normal platelet counts and 36.36% had thrombocytopenia. Of the four maternal mortalities, 25% of them had normal platelet counts and 75% had thrombocytopenia. Of the four eclampsia mothers who had acute renal failure, 50% had normal platelet counts.
and 50% had thrombocytopenia. Of the six eclampsia mothers who developed pulmonary edema, 100% of them had normal platelet counts.

This is similar to the studies of Leduc et al., Priyadarshini and Mohanty, Jambhulkar et al., Prieto et al., Mishra et al., Mohapatra et al., and Awolola and Enaruna. Leduc et al., study on coagulation profile in severe pre-eclampsia observed thrombocytopenia is reported frequently in severe pre-eclampsia. There is progressive fall of mean platelet count with the increasing severity of disease.

In the present study, of the eight neonatal deaths, 50% were among those of eclampsia mothers with normal platelet count and 5% among those with thrombocytopenia. Out of six still births, 83.33% were among those of eclampsia mothers with normal platelet count and 16.66% were among those with thrombocytopenia. Out of 10 LBW babies, 80% were among those of eclampsia mothers with normal platelet count and 20% among those with thrombocytopenia. Out of five VLBW babies, 100% were among those of eclampsia mothers with normal platelet count. Out of seven babies with 5 min Apgar <7, 85.71% were among those of eclampsia mothers with normal platelet count and 14.28% were among those with thrombocytopenia. Out of 52 premature babies, 86.53% were among those of eclampsia mothers with normal platelet count and 13.56% were among those with thrombocytopenia. Out of 10 IUGR babies, 80% were among those of eclampsia mothers with normal platelet count and 20% were among those with thrombocytopenia.

In our study, of the 46 eclampsia mothers who underwent operative intervention, 93.47% had normal BT and 6.52% had deranged BT. Of the 11 eclampsia mothers who received intensive care, 54.54% of them had normal BT and 45.45% had deranged BT. Of the four maternal mortalities, 25% of them had normal BT and 75% had deranged BT. Of the four eclampsia mothers who had acute renal failure, 100% had normal BT. Of the six eclampsia mothers who developed pulmonary edema, 83.33% of them had normal BT and 16.66% had deranged BT. Of the 10 eclampsia mothers who had PRES, 100% of them had normal BT. Of the five eclampsia mothers who had DIC, 80% of them had normal BT and 20% had deranged BT. This is comparable to the study of McDonagh et al.

Limitations of the study
The present study has some limitations. The sample size was small. Therefore, further studies should be conducted with bigger sample size and hospitals in rural and urban areas.

CONCLUSION
In the present study, eclampsia accounted for 2.3% of all deliveries. Normal pregnancy is a procoagulant state which is aggravated in PIH because of the constant endothelial damage that causes repeated activation of the coagulation cascade, leading to consumption of platelets and coagulation factors. This leads to maternal and fetal complications. Hence, relevant investigations need to be promptly done to identify the derangement of the coagulation profile in cases of eclampsia and pre-eclampsia which can alert the obstetrician of the severity of the disease so that appropriate and timely management can be initiated to prevent adverse outcomes. Health workers need to be instructed to ensure 100% registration of pregnant women and provide good quality of ANC including all essential components, especially record of weight, blood pressure, and urine analysis with an appropriate system of referral to tertiary care center at the earliest. All family physicians and medical officers need to be advised to follow a standard management protocol in a case of pre-eclampsia and eclampsia with an awareness for prompt referral of women who require to be managed by specialists. A well-equipped obstetric and neonatal intensive care unit manned by a team of consultant with special expertise need to be made available in every tertiary care center to provide the best maternal and fetal outcomes.

ACKNOWLEDGMENTS
Authors would like to acknowledge the patients who participated in this research study.

REFERENCES
1. Duley L, Matar HE, Almerie MQ and Hall DR. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev. 2010;2010(8):CD007388. https://doi.org/10.1002/14651858.CD007388.pub2
2. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol. 1992;99(7):547-553. https://doi.org/10.1111/j.1471-0528.1992.tb13818.x
3. Barua A, Mundle S, Bracken H, Easterling T and Winikoff B. Facility and personnel factors influencing magnesium sulphate use for eclampsia and pre-eclampsia in 3 Indian hospitals. Int J Gynecol Obstet. 2011;115(3):231-234. https://doi.org/10.1016/j.ijgo.2011.07.016
4. World Health Organisation International Collaborative Study of Hypertensive Disorders of pregnancy. Geographic variation in the incidence of hypertension in pregnancy. Am J Obstet Gynecol. 1988;158(1):80-83.
5. Swain S, Ojha KN, Prakash A and Bhatia BD. Maternal and perinatal mortality due to eclampsia. Indian Pediatr. 1993;30(6):771-773.
6. Walker JJ. In: Dasgupta P, editor. Modern Management of Pre-
Eclampsia and Eclampsia in Recent Advances in Obstetric and 
Gynaecology. Vol. 3. New Delhi: Jypee Brothers; 1997. p. 78-97.
7. Krishna Menon MK. The evolution of the treatment of eclampsia. 
J Obstet Gynaecol Br Commonwealth 1961;68:417-26.
8. Vanawalla NY, Ghamande S and Ingle KM. A five year analysis 
of eclampsia. J Obstet Gynecol India. 1989;39:513-515.
9. Suman G and Somegowda S. Maternal and perinatal outcome 
eclampsia in a district hospital. J Obstet Gynecol India. 
2007;57:324.
10. Singh K, Medhi R and Bhattacharjee AK. Book of Abstract.,
33rd AICOG, Guwahati 2010. p. 17.
11. Priyadarshini G and Mohanty RR. Assessment of coagulation 
profile and its correlation with Severity of preeclampsia in women 
of Odisha comparative cross-sectional study. Int J Basic Appl 
Physiol. 2014;3(1):111-116.
12. Awolola OO and Enaruna NO. Determination of coagulopathy 
complicating severe preeclampsia and eclampsia with platelet 
count in a University hospital, South-South, Nigeria. Trop J 
Obstet Gynaecol. 2016;33(2):179-184. 
https://doi.org/10.4103/0189-5117.192220
13. Mishra DP, Choudhury S and Tudu B. Evaluation of coagulation 
indices in preeclampsia and eclampsia. J Evid Based Med 
Healthc. 2019;6(17):1316-1320. 
https://doi.org/10.18410/jebmh/2019/272
14. Leduc L, Wheeler JM, Kirshon B, Mitchell P and Cotton DB. 
Coagulation profile in severe preeclampsia. Obstet Gynecol. 
1992;79(1):14-18.
15. Jambhulkar S, Shrikhande A, Shrivastava R and Deshmukh K. 
Coagulation profile in pregnancy induced hypertension. Indian J 
Hematol Blood transfus. 2001;19(1):3-5.
16. Prieto JA, Mastrobettista JM and Blanco JD. Coagulation 
studies in patients with marked thrombocytopenia due to severe 
preeclampsia. Am J Perinatol. 1995;12(3):220-222. 
https://doi.org/10.1055/s-2007-994457
17. Mohapatra S, Pradhan BB, Satpathy UK, MohantyA and 
Pathnaik JR. Platelet estimation: Its prognostic value in 
pregnancy induced hypertension. Indian J Physiol Pharmacol. 
2007;51(2):160-164.
18. McDonagh RJ, Ray JG, Burrows RF and Vermeulen MJ. Platelet 
count may predict abnormal bleeding time among pregnant 
women with hypertension and preeclampsia. Can J Anaesth. 
2001;48(6):563-569. 
https://doi.org/10.1007/BF03016833

Authors' Contributions: 
APB and KKP – Involved in the diagnosis and management of the cases. APB and RD – Did the literature search. KKP and APB – Wrote the manuscript.

Work attributed to: 
Department of Obstetrics and Gynaecology, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India.

Orcid ID: 
Dr. Ashrulina Pal Banerjee - https://orcid.org/0000-0001-9356-1605
Dr. Kajal Kumar Patra - https://orcid.org/0000-0001-8901-537X
Dr. Ritam De - https://orcid.org/0000-0003-3384-9361

Source of Support: Nil, Conflicts of Interest: None declared.